Neurol. pro Praxi, 2006; 2: 108-110

Farmakoterapie pokročilé Parkinsonovy nemoci

prof. MUDr. Petr Kaňovský, CSc.1, MUDr. Igor Nestrašil3,2, MUDr. Martin Nevrlý1, MUDr. Pavel Ressner5,4
1 Neurologická klinika FN a LF UP Olomouc
2 I. neurologická klinika LF MU a FN u sv. Anny Brno
3 Neurologická ambulance, Masarykův onkologický ústav, Brno
4 Centrum pro diagnostiku a léčbu extrapyramidových onemocnění a kognitivních poruch
5 Neurologická klinika FNsP Ostrava-Poruba

Parkinsonova nemoc se ve většině případů po 5–7 letech dostává do stadia, které označujeme jako pokročilé stadium nemoci. Příčinou je nejen progrese nemoci samotné, ale i komplikace, které vyvolává dopaminergní terapie. V takovémto stadiu nemoci je nezbytná snaha o optimalizaci léčby a o pozitivní ovlivnění všech symptomů pokročilého stadia. V současné době existuje řada medikamentů, které lze v této fázi použít, nicméně nezbytná je znalost všech možností farmakologické léčby před rozhodnutím o použití optimální varianty v každém individuálním případě.

Keywords: Klíčová slova: Parkinsonova nemoc, pokročilé stadium, inhibitory COMT, agonisté dopaminu.

Published: May 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kaňovský P, Nestrašil I, Nevrlý M, Ressner P. Farmakoterapie pokročilé Parkinsonovy nemoci. Neurol. praxi. 2006;7(2):108-110.
Download citation

References

  1. Bilici A, Karadag B, Doventas A, Erdincler DS, Cetinkaya S, Ogut G, Tezcan V, Beger T. Retroperitoneal fibrosis caused by pergolide in patient with Parkinson´s disease. Neth J Med. 2004; 62(10): 389-92.
  2. Curran MP, Perry CM. Cabergoline: a review of its use in the treatment of Parkinson's disease. Drugs. 2004; 64(18): 2125-41. Go to original source... Go to PubMed...
  3. Jenner P. Pharmacology of dopamine agonists in the treatment of Parkinson's disease. Neurology. 2002; 58(4 Suppl 1): S1-8. Go to original source... Go to PubMed...
  4. Kaynak D, Kiziltan G, Kaynak H, Benbir G, Uysal O. Sleep and sleepiness in patients with Parkinson's disease before and after dopaminergic treatment. Eur Neurol 2005 Mar; 12(3): 199-207. Go to original source... Go to PubMed...
  5. Paci C, Sanguigni S, Carboni T, Gobbato R, Curatola L. The use of entacapone in patients with advanced Parkinson's disease: 2 years' experience. Neurol Sci. 2003; 24(3): 197-8. Go to original source... Go to PubMed...
  6. Reimer J, Grabowski M, Lindvall O, Hagell P. Use and interpretation of on/off diaries in Parkinson´s disease. J Neurol Neurosurg Psychiatry 2004, 75: 396-4009. Verhagen Metman L. Recognition and treatment of response fluctuations in Parkinson's disease. Amino Acids 2002; 23: 141-5. Go to original source... Go to PubMed...
  7. Schrag A. Entacapone in the treatment of Parkinson's disease. Lancet Neurol. 2005; 4(6): 366-70. Go to original source... Go to PubMed...
  8. Swope DM. Rapid treatment of, ,wearing off" in Parkinson's disease. Neurology 2004, 62 (suppl. 4): S27-S31. Go to original source... Go to PubMed...
  9. Verhagen Metman L. Recognition and treatment of response fluctuations in Parkinson's disease. Amino Acids 2002; 23: 141-5. Go to original source... Go to PubMed...
  10. Widnell KL, Comella C. Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations. Mov Disord. 2005; 20 Suppl 11: S30-7. Go to original source... Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.